![[personal profile]](https://www.dreamwidth.org/img/silk/identity/user.png){kind=small}
chuka_lisМогут быть ответственны за часть неврологических симптомов и повреждения мозга у ковидных больных (и долгоковидников тоже).
Англичане обнаружили ассоциации между тяжестью симптомов и неврологических осложнений при ковиде, и количеством маркеров повреждения мозга (neurofilament light [NfL], Glial Fibrillary Acidic Protein [GFAP]), а после выздоровления- еще и с наличием повышенных уровней цитокинов (IL-6, TNFα иIL-10) и аутоантител в крови (не только к сурфактантным белкам клеток легких (у 8.8% выздоровевших после тяжелого ковида), но и к гликопротеинам, ассоциированным с миелином нервных волокон (9.6% случаев), и к другим"своим" антигенам).
У пациентов с долгим ковидом, не зависимо от тяжести ковида (приведшего к постковиду), кроме анутоантител класса М,определялся в крови маркер Тау, свидетельствующий о продолжающихся повреждения в нервной ткани, до 4 месяцев (дольше не меряли).
COVID-19 has been associated with many neurological complications including stroke, delirium and encephalitis. Furthermore, many individuals experience a protracted post-viral syndrome which is dominated by neuropsychiatric symptoms, and is seemingly unrelated to COVID-19 severity. The true frequency and underlying mechanisms of neurological injury are unknown, but exaggerated host inflammatory responses appear to be a key driver of severe COVID-19 more broadly. We sought to investigate the dynamics of, and relationship between, serum markers of brain injury (neurofilament light [NfL], Glial Fibrillary Acidic Protein [GFAP] and total Tau) and markers of dysregulated host response including measures of autoinflammation (proinflammatory cytokines) and autoimmunity. Brain injury biomarkers were measured using the Quanterix Simoa HDx platform, cytokine profiling by Luminex (R&D) and autoantibodies by a custom protein microarray. During hospitalisation, patients with COVID-19 demonstrated elevations of NfL and GFAP in a severity-dependant manner, and there was evidence of ongoing active brain injury at follow-up 4 months later. Raised NfL and GFAP were associated with both elevations of pro-inflammatory cytokines and the presence of autoantibodies; autoantibodies were commonly seen against lung surfactant proteins as well as brain proteins such as myelin associated glycoprotein, but reactivity was seen to a large number of different antigens. Furthermore, a distinct process characterised by elevation of serum total Tau was seen in patients at follow-up, which appeared to be independent of initial disease severity and was not associated with dysregulated immune responses in the same manner as NfL and GFAP.
Англичане обнаружили ассоциации между тяжестью симптомов и неврологических осложнений при ковиде, и количеством маркеров повреждения мозга (neurofilament light [NfL], Glial Fibrillary Acidic Protein [GFAP]), а после выздоровления- еще и с наличием повышенных уровней цитокинов (IL-6, TNFα иIL-10) и аутоантител в крови (не только к сурфактантным белкам клеток легких (у 8.8% выздоровевших после тяжелого ковида), но и к гликопротеинам, ассоциированным с миелином нервных волокон (9.6% случаев), и к другим"своим" антигенам).
У пациентов с долгим ковидом, не зависимо от тяжести ковида (приведшего к постковиду), кроме анутоантител класса М,определялся в крови маркер Тау, свидетельствующий о продолжающихся повреждения в нервной ткани, до 4 месяцев (дольше не меряли).
COVID-19 has been associated with many neurological complications including stroke, delirium and encephalitis. Furthermore, many individuals experience a protracted post-viral syndrome which is dominated by neuropsychiatric symptoms, and is seemingly unrelated to COVID-19 severity. The true frequency and underlying mechanisms of neurological injury are unknown, but exaggerated host inflammatory responses appear to be a key driver of severe COVID-19 more broadly. We sought to investigate the dynamics of, and relationship between, serum markers of brain injury (neurofilament light [NfL], Glial Fibrillary Acidic Protein [GFAP] and total Tau) and markers of dysregulated host response including measures of autoinflammation (proinflammatory cytokines) and autoimmunity. Brain injury biomarkers were measured using the Quanterix Simoa HDx platform, cytokine profiling by Luminex (R&D) and autoantibodies by a custom protein microarray. During hospitalisation, patients with COVID-19 demonstrated elevations of NfL and GFAP in a severity-dependant manner, and there was evidence of ongoing active brain injury at follow-up 4 months later. Raised NfL and GFAP were associated with both elevations of pro-inflammatory cytokines and the presence of autoantibodies; autoantibodies were commonly seen against lung surfactant proteins as well as brain proteins such as myelin associated glycoprotein, but reactivity was seen to a large number of different antigens. Furthermore, a distinct process characterised by elevation of serum total Tau was seen in patients at follow-up, which appeared to be independent of initial disease severity and was not associated with dysregulated immune responses in the same manner as NfL and GFAP.
![[community profile]](https://www.dreamwidth.org/img/silk/identity/community.png){kind=small}